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The folate receptor (FR) is a 38 kDa glycosylphosphatidylinositol-anchored protein that binds to the vitamin folic acid with high affinity (KD < 1 nM). Following binding, rapid endocytosis delivers a fraction of the receptors into a low pH compartment where dissociation of the vitamin from its receptor is promoted. Interestingly, covalent conjugation of small molecules, proteins, and even liposomes to the γ-carboxyl moiety of folic acid does not alter its ability to bind the folate receptor and undergo endocytosis by receptor bearing cells. The FR-α isoform is present primarily in placenta, kidney, malignant tumors and various cancer cell lines. It is also expressed on the apical surfaces of some normal epithelia (e.g. bronchioalveolar cells of the lungs and choroid plexus of the brain), but the receptor at these epithelial sites is generally inaccessible to parenterally administered drugs. It has recently been discovered that activated (but not resting) synovial macrophages, taken from patients diagnosed with rheumatoid arthritis, possess a functionally active FR-β. The accumulated data also strongly demonstrate that activated macrophages can be selectively targeted with folate conjugates in cancer tissue and arthritic joints, a capability that opens new possibilities for the diagnosis and treatment of rheumatoid arthritis. The prevalence of FR overexpression among human tumors and activated macrophages makes it a good marker for targeted drug delivery to cancer and arthritis. Although FR-targeting has been found to enhance intracellular delivery of attached proteins, liposomes, viruses, antisense oligonucleotides, gene therapy vectors, polymeric drug carriers, imaging compounds, and neutron activation agents it has not yet been reported to improve net uptake of low molecular weight chemotherapeutic compounds, except in the case of certain antifolates. 
	The objective of this study was to utilize the folate-receptor overexpression in cancer cells and inflammatory macrophages for enhanced and site-specific delivery of anti-cancer and anti-rheumatic drugs to their respective sites. For this purpose folate was conjugated to different polymers such as PAMAM dendrimers, PLGA and loaded with drugs and evaluated for their targeting ability. Also folate was coupled to the drugs through a linker (pro-drug/polymer-drug conjugate concept) and determined for their enhanced site-specific targeting ability.
	The first part of the study deals with the folate mediated targeting of anti-arthritic drug indomethacin to inflammation. Indomethacin is a non-steroidal anti-inflammatory drug used for the management of rheumatoid arthritis, osteoarthritis and acute gout but has a limited efficacy coupled with gastric intestinal hemorrhage and other side effects such as renal dysfunction with conventional therapies. Site-specific delivery of indomethacin to the target site remains the best choice to overcome the side effects and to increase its efficacy.
	Poly(amidoamine) (PAMAM) dendrimers offer a defined branched chain structure capable of carrying multiple molecular entities that are either linked covalently to its surface or are encapsulated in its interior space. The controlled multivalency of dendrimers can be used to attach several drug molecules, targeting groups and other agents (solublizing/sensing) to the periphery of the dendrimers in a well defined manner. Dendrimers conjugates have been used for delivering drugs, DNA, radionucleides, MRI contrast agents and boron for neutron capture therapy.
	Full generation PAMAM dendrimers with amino terminal groups are suitable for direct coupling of folic acid and G4 with 64 surface amino groups was selected for the present study. Folic acid was coupled to the surface amino groups of G4-PAMAM dendrimer (G4D) via a carbodiimide reaction and loaded with indomethacin. Folate-PAMAM dendrimer conjugates with different degree of folate substitutions were synthesized and characterized by 1H-NMR and IR spectroscopy. Approximately 4, 13 and 21 folate molecules were conjugated to G4D when the molar ratio of folate was 8, 16 and 32 moles, respectively. The drug content and percent encapsulation efficiency increased with increasing folate content for the dendrimer conjugates. The in vitro release profile indicated a more controlled release of the drug with increasing folate content. Pharmacokinetic and tissue distribution studies in arthritic rats had shown preferential higher accumulation of indomethacin at the inflamed paw by the folate conjugates when compared with dendrimer at equivalent dose. The plasma concentration profile showed a biphasic curve indicating rapid distribution followed by slow elimination. The AUC0–∞, half-life and residence time of indomethacin in inflamed paw was higher for folate-dendrimer conjugates. The time-averaged relative drug exposure (re) of the drug in paw and overall drug targeting efficiency (Te) were higher for folate conjugate with 21 folate moieties (4.1 and 2.78, respectively) when compared with DNI (1.91 and 1.88, respectively). Among the conjugates, the formulation with 21 folate molecules (FN3) was found to possess good encapsulation efficiency, controlled release nature and highest targeting efficiency to the inflammatory region. This study demonstrated the superiority of active targeting over dendrimer mediated passive targeting and also for the first time, folate-mediated targeting of an anti-arthritic drug to the inflammatory tissues.
	The next formulation was prepared with anionic dendrimer (carboxylate terminated G3.5 PAMAM) as targeted drug delivery systems. This dendrimer has 64 surface carboxylate groups, which were conjugated to folate through a PEG spacer. Folate-PEG-PAMAM conjugates were synthesized by a two step reaction through a carbodiimide mediated coupling reaction. Conjugates with three different folate-PEG substitutions were prepared and loaded with indomethacin by continuous shaking method. Characterization of the conjugates revealed approximately 7, 11 and 20 folate-PEG moieties were attached to each molecule of G3.5 PAMAM dendrimer. Drug loading was significantly increased in the folate-PEG conjugates when compared with the non-conjugated dendrimer. The number of folate-PEG molecules influenced the percent drug loading into conjugates with maximum loading observed for the conjugate with 20 folate-PEG molecules attached. The in vitro release profile revealed the controlled release nature of the folate-PEG conjugates. The plasma indomethacin levels in arthritic rats showed a biphasic curve with rapid distribution phase followed by a slower elimination phase. The plasma pharmacokinetic parameters illustrated an increased AUC, half-life and mean residence time for the folate-PEG conjugates. The tissue distribution studies had shown high exposure (AUC) of the drug to stomach, heart and RES organs in the control group. The folate-PEG conjugates had shown reduced uptake by RES organs and in particular the exposure to stomach was nearly one-tenth of the non-conjugated dendrimer indicating the limited gastric-related side effects of indomethacin. Also the folate-PEG conjugates delivered significantly higher amount of drug to the inflamed paw than the control and dendrimer groups. Among the different folate-PEG conjugates, the conjugate with 7 folate-PEG molecules exhibited better overall drug targeting efficiency (3.44) and higher relative exposure of drug to the inflammatory region (2.37). This folate-PEG-PAMAM conjugate remains the ideal candidate for site-specific drug delivery with high efficiency to target the inflammatory tissues accompanied by reduced side effects.
	The polymeric prodrug conjugates increase aqueous solubility, enhance biodistribution and retain the inherent pharmacological properties of the drug intact. Utilizing this strategy, indomethacin nanoconjugates were synthesized by conjugating folic acid and indomethacin to α- and ω-terminal end group of poly(ethylene glycol)-bis-amine (FPI). FPI nanoconjugate micelles loaded with indomethacin were produced by both dialysis and emulsification method. The emulsification method yielded smaller particle size (179 nm) with maximum encapsulation efficiency at 25% drug loading. The in vitro release profile showed that the release of indomethacin from this micellar nanoconjugate could be controlled over 5 days. The plasma pharmacokinetics of the micellar nanoconjugate in arthritic rats had shown an increased circulation half-life of indomethacin. The tissue distribution studies revealed higher accumulation of the drug in inflammatory paw. The overall drug targeting efficiency (Te) value of micellar nanoconjugates for inflamed paw was 3.9 folds higher than the control and the time-averaged relative drug exposure (re) value was higher (23.86) indicating the potential of this micellar drug nanoconjugate for active targeting to inflammation in rheumatoid arthritis.
	In brief summary, all these folate targeted formulations exhibited enhanced site specific drug delivery to the inflammatory region of arthritis and serve as better carriers for indomethacin by reducing its side-effects and improving drug delivery at the target site.
	The second part of the study deals with the folate-mediated targeting of anti-cancer drug paclitaxel to tumor cells and their in vivo pharmacokinetics and biodistribution pattern in healthy rats. Paclitaxel is used for its antineoplastic action against malignant neoplasms of the breast and ovary, and in advanced non-small cell lung cancer, but has also been tried in other malignancies including tumors of the head and neck, prostate, and Kaposi’s sarcoma. Paclitaxel is also active against malignant gliomas and brain metastases. However, low to undetectable levels of the drug were found in the normal brains as well as in tumor brain tissue. Paclitaxel has been shown to be a substrate for the multidrug resistance 1 (MDR 1) expressed protein, p-glycoprotein (p-gp). Thus targeted delivery of paclitaxel to cancer cells and to brain remains the best choice to overcome the above mentioned barriers.
	Paclitaxel was conjugated to the carboxyl end groups of G3.5 PAMAM dendrimer and coupled with folate-PEG chains. Utilizing the pro-drug concept, the drug was also directly conjugated to folate-PEG-amine through a carbodiimide mediated coupling reaction after converting the hydroxyl group into a carbonate derivative. About 43 to 44 molecules of paclitaxel were found conjugated and the number of folate-PEG chains attached was 10. All these formulations exhibited controlled release over 12 days with less than 25% of drug released. When compared with paclitaxel-dendrimer conjugate, the release rate of folate conjugate was decreased in both PBS and rat plasma, which can be attributed to the more shielding effect provided by the surface folate-PEG chains. None of these conjugates were found to be hemolytic upto 5 mg/ml. The in vitro cytotoxicity of these conjugates confirmed the selective cytotoxicity towards the folate receptor positive (HeLa) cells. Also the in vitro uptake studies confirmed folate receptor mediated uptake of folate coupled conjugates. The in vivo plasma pharmacokinetics indicated increased bioavailability of all the conjugates with increased mean residence time and circulation half-life. Biodistribution studies revealed the brain targeting efficiency of the folate conjugates. Thus the folate conjugates of paclitaxel indicate a promising approach for overcoming the blood brain barrier and enhanced paclitaxel delivery to the brain.
	Finally, folate targeted copolymers comprising of PEG and PLGA (folate-PEG-PLGA, FPLG) was synthesized by a two step reaction utilizing the carbodiimide mediated coupling reaction. NMR and FTIR spectroscopy studies confirmed the conjugation of folate-PEG to PLGA. The DSC thermograms revealed the shift in Tg of FPLG confirming the formation of new copolymer. Nanoparticles with 0%, 50% and 100% FPLG (NP1, NP2 and NP3, respectively) were prepared by single emulsion method. Folate-PEG coupling increased the mean size of the nanoparticles from 258.7 nm to 290-295 nm. The shift in the zeta potential to positive charge and the XPS confirmation of the presence of nitrogen groups in N1s region prove the surface domination of nanoparticles by folate groups in nanoparticles prepared with FPLG. The encapsulation efficiency increased with increasing folate-PEG composition in the polymer matrix. The in vitro release profile indicated increased release rate for NP3 followed by NP2 in PBS and in rat plasma. Paclitaxel was released in controlled manner by all the nanoparticles with the release exceeding 12 days. Cytotoxicity studies revealed decreased IC50 for NP2 and NP3 in folate receptor positive cell lines (HeLa cells) and similar IC50 values as that of NP1 in folate receptor negative cell lines (A549 cells) indicating the selective cytotoxicity. The cell uptake studies confirmed the enhanced uptake of NP2 and NP3 by folate expressing cell lines through receptor mediated endocytosis which was inhibited in presence of folic acid due to competitive inhibition and saturation of the folate receptors. Thus these folate-PEG conjugated PLGA copolymers serve as a better carrier for paclitaxel with high encapsulation efficiency and selective targeting and cytotoxicity to folate receptor expressing cells.
	To summarize, the folate targeted paclitaxel conjugates and nanoparticles exhibited enhanced cytotoxicity to folate-receptor positive cells with enhanced uptake by these folate-receptor positive cells, thereby overcoming the side effects of paclitaxel. Also the folate conjugates were found to overcome the blood brain barrier and thereby increase the drug exposure to brain, which is of significant consequence in treating brain tumors.
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